Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor

Cancer Letters

Volumn 349, Issue 1, 2014, Pages 45-50

  Ryu, Byung Jun ^a   Kim, Sunmin ^b   Min, Bora ^a   Kim, Keon Young ^b   Lee, Jin Soo ^c   Park, Whui Jung ^c   Lee, Hyuk ^a   Kim, Seong Hwan ^a   Park, SangYoun ^b  

^a Korea Research Institute of Chemical Technology   (South Korea)

^b Soongsil University   (South Korea)

^c DongWha Pharm Ind Co   (South Korea)

Author keywords

Cancer; Drug discovery; HTS; PAK4; Protein kinase; X ray crystallography

Indexed keywords

2N [2 (1H INDOL 3 YL) EHTYL] 4N (1H INDAZOL 5 YL) 6 METHOXY 1,3,5 TRIAZINE 2,4 DIAMINE; ADENOSINE TRIPHOSPHATE; ANDROGEN RECEPTOR; DW 1759; KY 04031; P21 ACTIVATED KINASE 4; PF 3758309; PHOSPHOTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; P21 ACTIVATED KINASE; PAK4 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL INVASION; CELL VIABILITY; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; THERMOSTABILITY; ANTAGONISTS AND INHIBITORS; CELL PROLIFERATION; CHEMISTRY; DRUG EFFECTS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; P21-ACTIVATED KINASES; PROTEIN KINASE INHIBITORS;

EID: 84901041726     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.03.024     Document Type: Article

References (28)

1. Maruta H. PAKS, RAC/CDC42 (p21)-Activated Kinases 2013, Elsevier.
2. Abo A., Qu J., Cammarano M.S., Dan C., Fritsch A., Baud V., Belisle B., Minden A. PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia. EMBO J. 1998, 17:6527-6540.
3. Qu J., et al. Activated PAK4 regulates cell adhesion and anchorage-independent growth. Mol. Cell. Biol. 2001, 21:3523-3533.
4. Qu J., Li X., Novitch B.G., Zheng Y., Kohn M., Xie J.-M., Kozinn S., Bronson R., Beg A.A., Minden A. PAK4 kinase is essential for embryonic viability and for proper neuronal development. Mol. Cell. Biol. 2003, 23:7122-7133.
5. Callow M.G., Zozulya S., Gishizky M.L., Jallal B., Smeal T. PAK4 mediates morphological changes through the regulation of GEF-H1. J. Cell Sci. 2005, 118:1861-1872.
6. Dan C., Kelly A., Bernard O., Minden A. Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J. Biol. Chem. 2001, 276:32115-32121.
7. Li Z., et al. P21-activated kinase 4 phosphorylation of integrin beta5 Ser-759 and Ser-762 regulates cell migration. J. Biol. Chem. 2010, 285:23699-23710.
8. Wells C.M., Whale A.D., Parsons M., Masters J.R., Jones G.E. PAK4: a pluripotent kinase that regulates prostate cancer cell adhesion. J. Cell Sci. 2010, 123:1663-1673.
9. Gnesutta N., Qu J., Minden A. The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis. J. Biol. Chem. 2001, 276:14414-14419.
10. Callow M.G., et al. Requirement for PAK4 in the anchorage-independent growth of human cancer cell lines. J. Biol. Chem. 2002, 277:550-558.
11. Ha B.H., Davis M.J., Chen C., Lou H.J., Gao J., Zhang R., Krauthammer M., Halaban R., Schlessinger J., Turk B.E., Boggon T.J. Type II p21-activated kinases (PAKs) are regulated by an autoinhibitory pseudosubstrate. Proc. Natl. Acad. Sci. USA 2012, 109:16107-16112.
12. Eswaran J., Lee W.H., Debreczeni J.E., Filippakopoulos P., Turnbull A., Fedorov O., Deacon S.W., Peterson J.R., Knapp S. Crystal structures of the p21-activated kinases PAK4, PAK5, and PAK6 reveal catalytic domain plasticity of active group II PAKs. Structure 2007, 15:201-213.
13. Murray B.W., Guo C., Piraino J., Westwick J.K., Zhang C., Lamerdin J., Dagostino E., Knighton D., Loi C.M., Zager M., Kraynov E., Popoff I., Christensen J.G., Martinez R., Kephart S.E., Marakovits J., Karlicek S., Bergqvist S., Smeal T. Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth. Proc. Natl. Acad. Sci. USA 2010, 107:9446-9451.
14. Guo C., McAlpine I., Zhang J., Knighton D.D., Kephart S., Johnson M.C., Li H., Bouzida D., Yang A., Dong L., Marakovits J., Tikhe J., Richardson P., Guo L.C., Kania R., Edwards M.P., Kraynov E., Christensen J., Piraino J., Lee J., Dagostino E., Del-Carmen C., Deng Y.L., Smeal T., Murray B.W. Discovery of pyrroloaminopyrazoles as novel PAK inhibitors. J. Med. Chem. 2012, 55:4728-4739.
15. Wells C.M., Abo A., Ridley A.J. PAK4 is activated via PI3K in HGF-stimulated epithelial cells. J. Cell Sci. 2002, 115:3947-3956.
16. Y.H. Chung, C.W. Lee, W.Y. Yang, H.D. Lee, W.J. Park, Y.Y. Chang, J.S. Lee, Methoxy-1,3,5-Triazine Derivatives as Antiviral Agents, WO Patent 2002/079187 A1. October 10, 2002.
17. D. Bouzida, L. Dong, C. Guo, Y. Hong, H. Li, J.T. Marakovits, A. Yang, J. Zhang, Pyrrolopyrazoles, Potent Kinase Inhibitors, WO Patent 2006/072831 A1. July 13, 2006.
18. Gill S.C., von Hippel P.H. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 1987, 182:319-326.
19. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 1997, 276:307-325.
20. McCoy A.J., Grosse-Kunstleve R.W., Storoni L.C., Read R.J. Likelihood-enhanced fast translation functions. Acta Cryst. 2005, D61:458-464.
21. Emsley P., Cowtan K. Coot: model-building tools for molecular graphics. Acta Cryst. 2004, D60:2126-2132.
22. Vagin A.A., Steiner R.A., Lebedev A.A., Potterton L., McNicholas S., Long F., Murshudov G.N. REFMAC5 dictionary: organisation of prior chemical knowledge and guidelines for its use. Acta Cryst. 2004, D60:2284-2295.
23. Ferguson A.D., Sheth P.R., Basso A.D., Paliwal S., Gray K., Fischmann T.O., Le H.V. Structural basis of CX-4945 binding to human protein kinase CK2. FEBS Lett. 2011, 585:104-110.
24. Lo M.C., Aulabaugh A., Jin G., Cowling R., Bard J., Malamas M., Ellestad G. Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. Anal. Biochem. 2004, 332:153-159.
25. Whale A.D., Dart A., Holt M., Jones G.E., Wells C.M. PAK4 kinase activity and somatic mutation promote carcinoma cell motility and influence inhibitor sensitivity. Oncogene 2013, 32:2114-2120.
26. Park M.H., Lee H.S., Lee C.S., You S.T., Kim D.J., Park B.H., Kang M.J., Heo W.D., Shin E.Y., Schwartz M.A., Kim E.G. P21-Activated kinase 4 promotes prostate cancer progression through CREB. Oncogene 2013, 32:2475-2482.
27. Schrantz N., da Silva Correia J., B.Fowler J., Ge Q., Sun Z., Bokoch G.M. Mechanism of p21-activated kinase 6-mediated inhibition of androgen receptor signaling. J. Biol. Chem. 2004, 279:1922-1931.
28. Sadar M.D. Small molecule inhibitors targeting the "achilles' heel" of androgen receptor activity. Cancer Res. 2001, 71:1208-2121.